Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients

Asan Medical Center

Status: Completed

Conditions: Graft Failure; Chronic Kidney Diseases; Acute Kidney Injury

Study type: Observational

Funder types: Other

Identifiers

NCT06340607

2023-0561

Details and patient eligibility

About

This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Full description

Acute kidney injury (AKI) after liver transplantation (LT) significantly affects patient and graft outcomes. The Albumin-Bilirubin (ALBI) score, an objective and sensitive index of liver function, has potential applicability in predicting outcomes following LT. This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Enrollment: 3,422 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• living donor liver transplantation recipients (≥18 years)

Exclusion criteria

• preoperative serum creatinine (sCr) > 1.4 mg/dL, diagnosed CKD or hepatorenal syndrome (HRS), or hemodialysis at baseline

Trial design

3,422 participants in 2 patient groups

Recipients with neohepatic ALBI ≥ -1.615

Description:

The ALBI score was calculated using the formula: (log10bilirubin × 0.66) + (albumin × -0.085), where bilirubin is measured in μmol/L and albumin in g/L. Recipients with neohepatic (post-reperfusion) ALBI ≥ -1.615

Recipients with neohepatic ALBI < -1.615

Description:

Recipients with neohepatic (post-reperfusion) ALBI \< -1.615